Gaucher Disease Drugs Market Size, Share & Trends Report

Gaucher Disease Drugs Market Size, Share & Trends Analysis Report By Type, By Therapy (Enzyme Replacement Therapy, Substrate Replacement Therapy), By Major Markets, And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-2-68038-599-1
  • Number of Pages: 84
  • Format: Electronic (PDF)

Table of Contents

Chapter 1 Methodology and Scope
                 1.1 Research Methodology
                 1.2 Research Scope and Assumptions
                 1.3 List to Data Sources
                 1.4 List of Abbreviations
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                 3.1 Disease Primer
                     3.1.1 Types
                     3.1.2 Symptoms
                     3.1.3 Complications
                 3.2 Epidemiology
                 3.3 Current Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
                 3.4 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
Chapter 4 Global Gaucher Disease Drugs Market Overview
                 4.1 Introduction and Market Overview
                     4.1.1 Segmentation, by type
                         4.1.1.1 Type 1
                         4.1.1.2 Type 2
                         4.1.1.3 Type 3
                     4.1.2 Segmentation, by therapy
                         4.1.2.1 Enzyme replacement therapy
                         4.1.2.2 Substrate replacement therapy
                     4.1.3 Segmentation, by major market
                         4.1.3.1 U.S.
                         4.1.3.2 EU5
                         4.1.3.3 Japan
                     4.1.4 Market size and forecast
                     4.1.5 Sales performance
                     4.1.6 Market dynamics among leading brands
                 4.2 Patent Expiry Schedule
                 4.3 Drivers and Challenges
                 4.4 Deals Landscape (2013 - 2018)
                 4.5 Pricing and Reimbursement
                 4.6 Emerging Markets
                 4.7 SWOT Analysis
Chapter 5 Gaucher Disease Drugs Market: Pipeline Intelligence
                 5.1 Pipeline Landscape
                     5.1.1 Drugs under Development
                 5.2 Key R&D Trends
                     5.2.1 Biomarkers
                     5.2.2 DNA Mutation Analysis
                 5.3 Late-Stage Pipeline
                 5.4 Profile of Disruptive Drugs
                     5.4.1 GZ402671
Chapter 6 Company Profiles
                 6.1 Sanofi Genzyme
                     6.1.1 Company Overview
                     6.1.2 Current Product Portfolio
                     6.1.3 Product Forecast Sales
                     6.1.4 Company - key news flow
                     6.1.5 Pipeline View
                     6.1.6 Pipeline Forecast
                     6.1.7 Catalysts and Event Calendar
                     6.1.8 SWOT Analysis
                 6.2 Shire Therapeutics
                     6.2.1 Company Overview
                     6.2.2 Current Product Portfolio
                     6.2.3 Product Forecast Sales
                     6.2.4 Company - key news flow
                     6.2.5 Pipeline View
                     6.2.6 Pipeline Forecast
                     6.2.7 Catalysts and Events Calendar
                     6.2.8 SWOT Analysis
                 6.3 Pfizer
                     6.3.1 Company Overview
                     6.3.2 Current Product Portfolio
                     6.3.3 Product Forecast Sales
                     6.3.4 Company - key news flow
                     6.3.5 Pipeline View
                     6.3.6 Pipeline Forecast
                     6.3.7 Catalysts and Events Calendar
                     6.3.8 SWOT Analysis
                 6.4 Johnson & Johnson
                     6.4.1 Company Overview
                     6.4.2 Current Product Portfolio
                     6.4.3 Product Forecast Sales
                     6.4.4 Company - key news flow
                     6.4.5 Pipeline View
                     6.4.6 Pipeline Forecast
                     6.4.7 Catalysts and Event Calendar
                     6.4.8 SWOT Analysis
Chapter 7 Market Outlook
                 7.1 Winners and Losers
                 7.2 Emerging Companies
                 7.3 What the Future Holds


List of Tables

Table 1 List of Abbreviation
Table 2 Clinical Features of Gaucher Disease
Table 3 Gaucher Disease Prevalence and Incidence - 2017
Table 4 Gaucher Disease Prevalence and Incidence Forecast, 2017A-2025E
Table 5 Gaucher Disease Drugs Market Size and Forecast (in USD Million)
Table 6 Geographic Sales Performance, by Seven Major Markets (in USD Million)
Table 7 Gaucher Disease Drugs Market, by Type (in USD Million)
Table 8 Gaucher Disease Drugs Market, by Therapy (in USD Million)
Table 9 Gaucher Disease Drugs - Patent Expiry Schedule
Table 10 Gaucher Disease Deals Landscape (2013-2018)
Table 11 Gaucher Disease Product Pricing
Table 12 Gaucher Disease Drugs in Development
Table 13 Late-Stage Gaucher Disease Pipeline
Table 14 Pipeline Forecast - Global Gaucher Disease Drugs
Table 15 Profile of Disruptive Drug: GZ402671
Table 16 Product Portfolio: Cerezyme
Table 17 Product Portfolio: Cerdelga
Table 18 Cerezyme Product Forecast Sales 2017A-2025E (in USD Million)
Table 19 CerdelgaProduct Forecast Sales 2017A-2025E (in USD Million)
Table 20 Sanofi Genzyme Pipeline View
Table 21 Sanofi Genzyme Catalysts and Event Calendar
Table 22 Product Portfolio: Vpriv
Table 23 Vpriv Product Forecast Sales 2017A-2025E (in USD Million)
Table 24 Shire Pipeline View
Table 25 Shire Catalysts and Event Calendar
Table 26 Product Portfolio: Elelyso
Table 27 Elelyso Product Forecast Sales 2017A-2025E (in USD Million)
Table 28 Pfizer Pipeline View
Table 29 Pfizer Catalysts and Event Calendar
Table 30 Product Portfolio: Zavesca
Table 31 Zavesca Product Forecast Sales 2017A-2025E (in USD Million)
Table 32 Johnson & Johnson Pipeline View
Table 33 Johnson & Johnson Catalysts and Event Calendar


List of Figures

Fig. 1 Current Prevalence Across Seven Major Markets - 2017
Fig. 2 Current Incidence Across Seven Major Markets - 2017
Fig. 3 Market Segmentation and Scope
Fig. 4 Geographic Sales Performance by Seven Major Markets 2017
Fig. 5 Gaucher Disease Drugs Market, by Type (2017)
Fig. 6 Gaucher Disease Drugs Market, by Therapy, 2017A-2025E (in USD Million)
Fig. 7 Gaucher Disease Drugs Market Trend, by Therapy (2017)
Fig. 8 U.S. Gaucher Disease Drugs Market, by Type (in USD Million)
Fig. 9 U.S. Gaucher Disease Drugs Market, by Therapy (in USD Million)
Fig. 10 U.K. Gaucher Disease Drugs Market, by Type (in USD Million)
Fig. 11 U.K. Gaucher Disease Drugs Market, by Therapy (in USD Million)
Fig. 12 Germany Gaucher Disease Drugs Market, by Type (in USD Million)
Fig. 13 Germany Gaucher Disease Drugs Market, by Therapy (in USD Million)
Fig. 14 Spain Gaucher Disease Drugs Market, by Type (in USD Million)
Fig. 15 Spain Gaucher Disease Drugs Market, by Therapy (in USD Million)
Fig. 16 France Gaucher Disease Drugs Market, by Type (in USD Million)
Fig. 17 France Gaucher Disease Drugs Market, by Therapy (in USD Million)
Fig. 18 Italy Gaucher Disease Drugs Market, by Type (in USD Million)
Fig. 19 Italy Gaucher Disease Drugs Market, by Therapy (in USD Million)
Fig. 20 Japan Gaucher Disease Drugs Market, by Type (in USD Million)
Fig. 21 Japan Gaucher Disease Drugs Market, by Therapy (in USD Million)
Fig. 22 Gaucher Disease Drugs Market Share Distribution, by Company (2017A-2025E)
Fig. 23 Market Trends & Outlook
Fig. 24 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 25 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 26 SWOT Analysis (Gaucher Disease Drugs Market)
Fig. 27 Pipeline Assets, by Phase
Fig. 28 SWOT Analysis (Sanofi Genzyme)
Fig. 29 SWOT Analysis (Shire Therapeutics)
Fig. 30 SWOT Analysis (Pfizer)
Fig. 31 SWOT Analysis (Johnson & Johnson)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon gvr sidebar D&B icon gvr sidebar

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.